MabPlex
San Diego, CA, United States mabplexinc.com From their website, Nov 2026
- GMP
Work here? Claim this listing
About
MabPlex provides CDMO services for biopharmaceuticals, including development and manufacturing of mAbs, recombinant proteins, ADCs, and bispecifics. It serves global partners from its US R&D site and manufacturing site in Yantai, China, with headquarters in Yantai, China.
Services
Regulatory Affairs
Supports regulatory strategy, meetings, IND/IMPD/CTA and BLA/MAA submissions, and dossier preparation in eCTD and non-eCTD formats.
CMC Strategy, Management and Communication
Provides CMC strategy consulting and CMC gap analysis for drug development programs.
Medium Manufacturing
Produces serum-free medium for mammalian cell culture for cell line development and cell culture process development.
Cell Line Development
Develops stable mammalian cell lines for antibody production, including CHO-based platforms.
Cell line development
Upstream Process Development
Offers cell culture screening, feeding strategy optimization, clarification development, tech transfer, and scale-up of bioreactor processes.
Downstream Process Development
Develops purification processes for biologics, including chromatography optimization, viral clearance development, and resin lifetime studies.
Formulation Process Development
Supports formulation optimization, stability studies, freeze-thaw testing, agitation/shaking stability, and lyophilization development.
Antibody Drug Conjugation Process Development
Develops ADC processes from linker/toxin synthesis through process characterization and scale-up.
11 more services
- Analytical Method Development
- Protein Expression
- Antibody Humanization
- Antibody Fc Engineering
- Chemical Synthesis
- Antibody Drug Conjugation Screening
- ADC Assay and Mechanism Study
- Cell Banking
- Protein Related Drug DS/DP Manufacturing
- ADC DS/DP Manufacturing
- Product Testing
- Turnaround
- Transient expression 6-8 weeks
- Short time (2 months)
- What to send
- Sequence of the mouse-origin monoclonal antibody
- Antibody intermediates
- Details about the project and/or challenge
Capabilities
- Assays and studies
- ADCs
- Process development
- CHO
- Antibodies
- Analytical development
- Bioreactors
16 more
- Mammalian expression
- DAR
- Free drug ratio
- Concentration
- Purity
- Identity
- Potency
- Antigen-binding activity
- Fc-receptor binding activity
- Cytotoxicity
- Endocytosis
- Serum stability
- Titer
- Protein concentration
- Osmolality
- Bacterial endotoxin
- Scale and capacity
- 0-500 mg proteins
- Up to 2000L
- 40 tons powder medium per year
- 1.4 million liters of liquid medium
- Broad range of conjugation scales from 10L to 150L
- Multiple production scales at 50L, 200L, 500L, 1000L and 2000L
- Milligram to kilogram scale
- Therapeutic areas
- CD20+ non-Hodgkin lymphoma
Instruments and platforms
- Ambr® system
Modalities and species
- Modalities
- Small molecule
- Antibody
- Bispecific
- ADC
- Recombinant protein
- Species and models
- CHO-K1
- DG44
- DXB11
- CHO-S
- Mouse
- Rat
- Human tumor cell lines
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Scope: manufacturing facilities
Details
- Type
- CRDMO
- Founded
- 2013
- Office
- 60 Middle Beijing Road Yantai, China (Shandong), Pilot Free Trade Zone HEADQUARTERS No. 60
- Sites
- Yantai, China
- Serves
- Globally, worldwide
Public records
- Biocom California CRO directory
- ADC, Bispecific, cGMP, Monoclonal Antibodies, recombinant protein source